What Has Been the Progress and Growth of the Oncolytic Adenovirus Market in Recent Years?
The oncolytic adenovirus market has seen considerable growth due to a variety of factors.
• The market scale for oncolytic adenovirus has seen robust expansion in the past years. The growth is expected to surge from $122.31 billion in 2024 to a projected $132.87 billion in 2025, marking a compound annual growth rate (CAGR) of 8.6%.
The historical period's growth is credited to a rise in cancer cases, escalating demand for specialized cancer treatments, increased funding for research and development, advancements in delivery procedures, and regulatory approvals.
What Is The Expected Growth In The Oncolytic Adenovirus Market Size Evolve over the Forecast Period?
The oncolytic adenovirus market is expected to maintain its strong growth trajectory in upcoming years.
• The market for oncolytic adenovirus is projected to witness substantial growth in the forthcoming years, reaching $183.22 billion in 2029 with a compound annual growth rate (CAGR) of 8.4%.
Factors contributing to the growth during this forecast period include the escalating prevalence and incidences of cancer, development of combination therapies, progress in regulatory standards and approvals, advancements in virus engineering technology and an upswing in investment in oncology research. The forecast period is expected to see significant trends such as progress in viral engineering techniques, cutting-edge drug delivery systems, improved accuracy in tumor targeting, advanced combinations of immunotherapy, and advancements in patient monitoring and diagnostic methods.
What Main Forces Are Fueling Expansion In The Oncolytic Adenovirus Market?
The surge in cancer cases is projected to boost the growth of the oncolytic adenovirus market. Cancer, a disease marked by unchecked cell proliferation and spread to other body parts, is on the rise due to factors such as aging populations, lifestyle choices, environmental exposures, genetic susceptibility, and enhanced detection techniques. The oncolytic adenovirus specifically targets and eliminates cancer cells, representing a promising solution to the escalating incidence of cancer. For example, in May 2024, the National Cancer Institute (NCI), a government agency based in the US, reported approximately 20 million fresh cases of cancer and 9.7 million deaths globally, with forecasts for 2040 indicating a rise to 29.9 million cases and 15.3 million deaths. Besides, the Australian Bureau of Statistics, a government agency based in Australia, reported in 2023 that 1.8% of Australians were diagnosed with cancer, with men (2.1%) being slightly more impacted than women (1.6%), particularly those over 75 years of age. As a result, the escalating incidence of cancer is propelling growth in the oncolytic adenovirus market.
What Are The Primary Segments In The Global Oncolytic Adenovirus Market?
The oncolytic adenovirus market covered in this report is segmented –
1) By Virus Type: Adenovirus Type 5-Based Oncolytic Viruses, Adenovirus Type 2-Based Oncolytic Viruses, Other Virus Types
2) By Application: Melanoma, Prostate Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Other Applications
3) By End-User: Hospitals, Cancer Research Institutes, Biotechnology Companies, Academic And Research Institutes
Subsegments:
1) By Adenovirus Type 5-Based Oncolytic Viruses: First-generation Adenovirus Type 5-based, Second-generation Adenovirus Type 5-based, Engineered Adenovirus Type 5-based
2) By Adenovirus Type 2-Based Oncolytic Viruses: First-generation Adenovirus Type 2-based, Second-generation Adenovirus Type 2-based, Engineered Adenovirus Type 2-based
3) By Other Virus Types: Modified Adenovirus Strains, Hybrid Adenovirus Types, Chimeric Adenoviruses
Pre-Book The Oncolytic Adenovirus Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Shaping The Oncolytic Adenovirus Market?
Major firms in the oncolytic adenovirus industry are emphasizing the use of combination treatments like VCN-01, integrating oncolytic virotherapy with chemotherapy for improved tumor targeting and enhanced treatment results. VCN-01 is an oncolytic adenovirus specifically engineered to infiltrate and eradicate cancer cells while simultaneously boosting chemotherapy effectiveness. For example, in May 2024, U.S.-based clinical-stage immuno-oncology firm, Theriva Biologics, declared that the U.S. Food and Drug Administration (FDA) had awarded Fast Track Designation (FTD) to their primary candidate, VCN-01. This Fast Track Designation pertains to VCN-01 when it is used in a combination treatment with gemcitabine and nab-paclitaxel for the management of metastatic pancreatic adenocarcinoma. VCN-01, an oncolytic adenovirus, has the capability to target and multiply within tumor cells, assisting in the breakdown of the tumor stroma, a significant impediment to successful cancer treatment.
Who Are the Key Players In The Oncolytic Adenovirus Market?
Major companies operating in the oncolytic adenovirus market are:
• Amgen Inc.
• Targovax ASA
• CG Oncology Inc.
• Replimune Group Inc.
• Imugene Limited
• Oncorus Inc.
• PsiOxus Therapeutics Ltd.
• Vyriad Inc.
• Transgene SA
• Valo Therapeutics Oy
• EpicentRx Inc.
• DNAtrix Inc.
• Shanghai Sunway Biotech Co. Ltd.
• TILT Biotherapeutics Ltd.
• Oncolys BioPharma Inc.
• Lokon Pharma AB
• GeneMedicine Co. Ltd.
• Akamis Bio Ltd.
• Genelux Corporation
• SillaJen Inc.
What Is The Most Dominant Region In The Oncolytic Adenovirus Market?
North America was the largest region in the oncolytic adenovirus market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic adenovirus market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
